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Cerebral malaria (CM) is a severe and rapidly progressing complica-
tion of infection by Plasmodium parasites that is associated with high
rates of mortality and morbidity. Treatment options are currently
few, and intervention with artemisinin (Art) has limited efficacy, a
problem that is compounded by the emergence of resistance to Art in
Plasmodium parasites. Rocaglates are a class of natural products
derived from plants of the Aglaia genus that have been shown to
interfere with eukaryotic initiation factor 4A (eIF4A), ultimately block-
ing initiation of protein synthesis. Here, we show that the rocaglate
CR-1-31B perturbs association of Plasmodium falciparum eIF4A
(PfeIF4A) with RNA. CR-1-31B shows potent prophylactic and thera-
peutic antiplasmodial activity in vivo in mouse models of infection
with Plasmodium berghei (CM) and Plasmodium chabaudi (blood-
stage malaria), and can also block replication of different clinical iso-
lates of P. falciparum in human erythrocytes infected ex vivo, includ-
ing drug-resistant P. falciparum isolates. In vivo, a single dosing of
CR-1-31B in P. berghei-infected animals is sufficient to provide pro-
tection against lethality. CR-1-31B is shown to dampen expression of
the early proinflammatory response in myeloid cells in vitro and damp-
ens the inflammatory response in vivo in P. berghei-infected mice. The
dual activity of CR-1-31B as an antiplasmodial and as an inhibitor of the
inflammatory response in myeloid cells should prove extremely valu-
able for therapeutic intervention in human cases of CM.
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Malaria is a severe threat to global health, with an estimated200–300 million cases annually and 445,000 deaths in 2016;
it accounts for ∼25% of pediatric deaths in endemic areas of
Africa (1–3). Malaria is also a significant threat to immunologically
naive travelers visiting or working in these areas (4). It is caused by
infection with members of the Plasmodium parasite family, with
clinical symptoms occurring at the blood stage, when Plasmodium
merozoites rapidly replicate and lyse erythrocytes (RBCs), leading to
anemia and high fever (2, 3). Furthermore, parasitized RBCs
(pRBCs) can adhere to the brain microvasculature, causing local
inflammatory and vascular tissue damage, which, in turn, leads to
cerebral malaria (CM), a severe syndrome that can rapidly evolve to
fatal encephalomyopathy and is mainly caused by Plasmodium fal-
ciparum (5, 6). Despite antimalarial treatment, CM has a high fatality
rate (18–40%) and up to one-third of survivors are afflicted with
neurocognitive deficits (7). The malaria problem is further compli-
cated by widespread parasite resistance to antimalarial drugs (8–12),
resistance of the Anopheles vector to insecticides (13), and the ab-
sence of an effective antimalaria vaccine despite enormous research
efforts (14).
Treatment of clinical malaria (uncomplicated disease) relies
entirely on antimalarial drugs, with artemisinin (Art) being the
most effective drug currently available (8). To avoid emergence of
Art resistance, Art monotherapy is discouraged and has been
replaced by Art combination therapy (ACT). ACTs are the cur-
rent WHO-approved standard of care for uncomplicated malaria.
ACTs include Art (artesunate, dihydro-Art, artemether, and
arteether) in combination with other drugs with pharmacokinetic
profiles showing longer circulation half-lives, such as mefloquine,
lumefantrine, amodiaquine, piperaquine, and sulfadoxine/pyri-
methamine (15, 16). In contrast, treatment options for CM are
few and are effective only when infection is detected early before
irreversible neurological symptoms (5–7). Administration of i.v.
artesunate is the WHO-approved first-line therapy, but efficacy
is limited, with 18–30% of CM cases still being fatal in large
randomized clinical trials in children and adults (17–19). Because
of the lack of equipotent drug alternatives, the recent emergence
and spread of Art resistance in different areas of Southeast Asia is a
major threat to global health (8, 12). Although the mechanisms of
Art resistance in Plasmodium are being characterized (20–24), it is
unclear that novel treatment options based on this knowledge will
be immediately forthcoming. Thus, there is a great urgency to de-
velop new therapeutic approaches to overcome Art resistance in the
malarial parasite. Likewise, increasing effectiveness of Art-based
therapies may improve the clinical outcome of CM, the most se-
vere and most difficult-to-treat complication of malaria.
Recent studies have pointed to initiation of protein synthesis as
a novel pharmacological target in P. falciparum for the develop-
ment of effective antimalarial drugs (25–27). Considering the
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functional and structural conservation of components of the
translation initiation machinery, we reasoned that known mam-
malian translation initiation inhibitors may display activity against
their Plasmodium counterparts, including antimalarial activity in
vivo. One target of this pathway that has been extensively scruti-
nized for small-molecule discovery is eukaryotic initiation factor
4F (eIF4F), a heterotrimeric complex required for ribosome re-
cruitment to capped (m7GpppX; X is any nucleotide) mRNAs
(28). eIF4F is composed of eIF4E, the cap-binding subunit;
eIF4A, a DEAD-box RNA helicase required to remodel the
mRNA 5′ leader region; and eIF4G, responsible for recruiting
the small ribosomal subunit (and associated factors) to the
mRNA (28). Rocaglates, the most characterized and potent
small molecules found to target eIF4F (29), are a class of natural
products derived from plants of the Aglaia genus (30) that in-
terfere with eIF4A activity in two ways. Rocaglates cause eIF4A
to clamp onto RNA, which, if it occurs in the mRNA 5′ leader
region, may act as a steric barrier to the initiation process, and
they deplete the eIF4F complex of its eIF4A helicase subunit
(31–34). The net result is reduced initiation complex formation.
Since eIF4F discriminates between mRNAs during the initiation
process, rocaglates, unlike general inhibitors of elongation, exert
a selective inhibitory effect on a subset of translating mRNAs
(31–34). They display tolerable safety profiles in vivo and exhibit
anticancer properties in tumor xenograft models (31, 35). In
addition, certain rocaglates can interfere with nuclear factor of
activated T cells (NFAT) and nuclear factor-kappa B (NF-κB)
signaling pathways in T cells in vitro (36, 37), suggesting po-
tential antiinflammatory properties.
In the present study, we have investigated the possible anti-
plasmodial activity of these compounds in vivo in mouse models of
blood-stage malaria (Plasmodium chabaudi) and experimental ce-
rebral malaria [ECM; Plasmodium berghei ANKA (PbA)], as well
as against multiple drug-resistant P. falciparum lines in vitro. We
show that rocaglates are potent antimalarial drugs, demonstrating
both direct antiplasmodial and antiinflammatory activities in vivo.
Single dosing is sufficient to protect mice against ECM induced by
PbA. Our data suggests that this effect is a consequence of roca-
glates suppressing both the activity of Plasmodium falciparum
eIF4A (PfeIF4A) and the excessive host inflammatory response.
Results
Rocaglates Interact with PfeIF4A. We investigated translation ini-
tiation as a potential new target for antimalarial drug discovery.
We noted a very strong sequence conservation (70% identity,
83% total similarity) between mammalian eIF4A1 and PfeIF4A
that extended beyond the conserved signature motifs that define
DEAD-box helicase family members (Fig. S1). Of note, human
and mouse parasites have near-complete sequence identity
conservation (Fig. S1).
We asked whether this strong structural similarity translated to
functional conservation, including interaction with small-molecule
modulators of mammalian eIF4A. Members of the rocaglates
family, characterized by a common cyclopenta[b]benzofuran skel-
eton (Fig. 1A), have been shown to be among the most potent
inhibitors of eIF4A, and structure–activity relationships have
identified highly potent translation inhibitors from within this family
(33, 35). CR-1-31B and (−)-SDS-1-021 act by increasing clamping
of eIF4A onto RNA with a concomitant decrease in eIF4F-
associated eIF4A, ultimately leading to impaired 43S ribosome
loading onto mRNA (31–35) (Fig. 1B). For both molecules, only
the (−) enantiomers are active; the molecules used in the current
study were prepared as single, bioactive enantiomers using our
previously published methods (38, 39) [Fig. S2; >95% pure com-
pounds, as confirmed by ultraperformance liquid chromatography
(UPLC)/evaporative light scattering detection (ELSD) analysis].
We tested whether PfeIF4A could also be targeted by roca-
glates. Both murine eIF4A1 (meIF4A1) and PfeIF4A were
expressed as recombinant proteins and purified from Escherichia
coli (Fig. 1C), and their ability to interact with [32P]-labeled RNA
was quantified in the presence and absence of two rocaglates:
silvestrol and the hydroxamate CR-1-31B (Fig. 1 D and E). Both
eIF4A proteins showed similar behavior, including low-level
RNA binding under control conditions, which was significantly
stimulated by silvestrol and CR-1-31B (approximately six- to 10-
fold increase). Clamping of eIF4A onto RNA, especially when in
the context of 5′ leaders, has the potential to block ribosome
scanning and could be one contributor to the inhibition of
translation imparted by these compounds. We directly tested the
effect of CR-1-31B on parasite protein synthesis by metabolic
labeling using [35S]-methionine incorporation in PbA pRBCs
(Fig. 1 F and G). In these experiments, cycloheximide (CHX)
was used as a positive control, while the antimalarial drug
chloroquine (CQ), which does not target translation, was used as
a negative control (Fig. 1 F and G). The effect of CR-1-31B on
protein synthesis was monitored directedly by SDS/PAGE of
P. berghei-labeled cell extracts and quantified by scintillation
counting. CR-1-31B could inhibit P. berghei protein synthesis
potently with an IC50 in the low nanomolar range, proving to be a
better inhibitor than CHX (Fig. 1 F and G). In addition, we have
measured the level of P. falciparum lactate dehydrogenase
(pLDH; the terminal enzyme of their glycolytic pathway) pro-
duced in in vitro cultures exposed to increasing concentrations of
CR-1-31B or CHX. The level of pLDH is potently reduced by
CR-1-31B with an IC50 of ∼3 nM, compared with an ∼300 nM
IC50 for CHX in both 3D7 and ItG P. falciparum isolates (Fig.
S3). Altogether, these initial observations strongly suggest that
rocaglates can efficiently interfere with PfeIF4A activity and
associated protein synthesis in a manner similar to their dem-
onstrated action on mammalian eIF4A.
Antiplasmodial Activity of Rocaglates in a Mouse Model of CM. The
potential antiplasmodial activity of rocaglates was assessed in
vivo in a murine model of ECM induced by infection with PbA.
In this model, mice infected with PbA develop blood-stage para-
sitemia detectable within 2 d. PbA-parasitized erythrocytes become
trapped in the brain microvasculature, leading to a pathological
inflammatory response in situ and appearance of drastic cerebral
symptoms (paralysis, seizure, and coma), with a clinical end point
reached by day 5–6 postinfection. Cerebral disease typically de-
velops with levels of blood parasitemia <10%. Using a prophylactic
treatment regimen where mice received daily dosing for 10 d
(starting at day −2 and ending at day +8), we observed that
treatment with the structurally related rocaglates CR-1-31B
(0.2 mg/kg) and SDS-1-021 (0.05 mg/kg) (Fig. 2A) almost
completely protected mice from ECM, with 80–90% of
treated mice surviving beyond day 15, while untreated mice
succumbed by day 6. Blood parasitemia monitored at days
3 and 6 postinfection showed a significant reduction of Plas-
modium-infected RBCs (pRBCs) in both the CR-1-31B– and
SDS-1-021–treated groups (Fig. 2B). These data indicate that
prophylactic treatment of mice with rocaglates can prevent
and significantly reduce mortality in the ECM model.
We next tested the capacity of rocaglates to act therapeutically
and cure an established PbA infection. For this, treatment of
PbA-infected mice with CR-1-31B (0.2 mg/kg) was performed
daily starting at various times postinfection (day 1, day 3, and day
4) and continuing to day 8 with disease outcome monitored. CR-
1-31B could significantly improve survival from PbA, even when
treatment was initiated later in the course of infection up to day
+4 (Fig. 2C). Similar results were obtained using SDS-1-021 (Fig.
S4). With both SDS-1-021 and CR-1-31B, the protective effect of
rocaglates was correlated with length of treatment and total dose
received (Fig. 2C and Fig. S4) and was associated with a signif-
icant reduction in blood parasitemia (measured at days 3, 6, and
8 postinfection; Fig. 2D). Interestingly, in CR-1-31B–treated
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animals, parasitemia measured at day 8 was lower than at day 6,
indicating that continued treatment with CR-1-31B caused a
reduction of parasitemia from the peak measured at day 6 (Fig.
2D). Finally, the therapeutic effect of CR-1-31B was found to be
dose-dependent: Animals dosed daily (starting at day 3 and
continuing to day 8) with CR-1-31B at either 0.1 or 0.2 mg/kg
were protected against lethal PbA-induced CM, while animals
receiving a lower daily dose of 0.02 mg/kg were as susceptible as
untreated controls (Fig. 2E). Parasitemia levels were also af-
fected in a dose-dependent manner (Fig. 2F and Fig. S5), with
the lower 0.02-mg/kg dose having no effect, while 0.1- and
0.2-mg/kg dosing caused a dose-dependent decrease in parasite
growth (measured at day 5 postinfection). These data suggest
that therapeutic intervention with rocaglates can prevent and
significantly reduce mortality in the ECM model.
Antiplasmodial Activity of Rocaglates Against Blood-Stage Parasites.
We conducted additional experiments to further validate the
effect of the rocaglate CR-1-31B on blood-stage replication of
the malarial parasite. First, we monitored the course of blood
parasitemia in a mouse mutant that does not develop CM fol-
lowing PbA infection due to an inactivating mutation in the
Themis gene, which causes impairment of T lymphocyte-driven
neuroinflammation (40). Control untreated Themis mice infected
A
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by gel electrophoresis and Coomassie blue staining. (D and E) Effect of silvestrol and CR-1-31B on binding and retention of purified meIF4A1 and PfeIF4A
recombinant proteins to radiolabeled RNA assessed by filter-binding assay; significance was determined using an unpaired two-tailed Student’s t test for the
indicated pairs (*P < 0.05; **P < 0.01). (F and G) Incorporation of [35S]-methionine to assess protein synthesis in PbA-infected blood and to test the effect of
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with PbA do not develop cerebral symptoms and survive past day 6
(compared with B6 controls) (Fig. 3A), but they do sustain pro-
gressive blood-stage parasite replication, leading to very high levels
of blood parasitemia by day 15 (>40%). Treatment of Themismice
with CR-1-31B (0.2 mg/kg) starting at either day 3 or day 5 post-
infection and continuing to day 11 caused a significant reduction in
blood parasitemia compared with untreated mice (Fig. 3B). Sec-
ond, we investigated the effect of CR-1-31B on replication of P.
chabaudi AS (PcA). PcA is a blood-stage parasite that does not
induce CM (41), with infected mice rather succumbing to hyper-
parasitemia and associated severe anemia by day 10 (Fig. 3 C and
D). Treatment of PcA-infected mice with CR-1-31B (0.2 mg/kg,
standard 4-d test) fully protected animals against lethality from
PcA infection. CR-1-31B–induced protection was associated with
a highly significant reduction in blood parasitemia measured daily
between days 3 and 6 postinfection (Fig. 3D), an effect that was
comparable to protection afforded by treatment with high-dose
artesunate (1.5 mg/kg) (Fig. 3D). These results strongly support
a direct antiplasmodial effect for CR-1-31B in vivo against mu-
rine Plasmodium parasites that induce blood-stage infection or
cerebral disease.
Antiplasmodial Activity of Rocaglates Against Human P. falciparum
Parasites. In dose–response studies with human erythrocytes in-
fected in vitro, we also monitored CR-1-31B activity against the
human P. falciparum malarial parasite (Fig. 4 A and B), using
previously described experimental conditions (42). In these ex-
periments, we used a number of different P. falciparum isolates,
including four freshly isolated from patients seen at the Uni-
versity of Toronto Health Network (UHN1–4), standard labo-
ratory lines (3D7, ItG, CS2, and FCR3), and isolates from
Thailand that display low levels of CQ and mefloquine resistance
(MS-97 lines). Infected blood cultures were exposed to various
concentrations of CR-1-31B or CQ for 48 h, and the effect of
drug exposure on parasite growth inhibition was monitored and
quantified (IC50) using a fluorescence-based assay (SYBR-Green
I) (Fig. 4 A and B). CR-1-31B showed strong activity against all
P. falciparum lines tested, with IC50 values in the low nanomolar
range, varying between 0.9 and 2.8 nM, whereas CQ had an IC50
average of ∼100 nM (Fig. 4C). Together, these results demon-
strate that CR-1-31B acts to block replication of human malarial
parasites, arguing for a possible therapeutic value of CR-1-31B
in clinical management of malaria.
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31B or(−)-SDS-1-021, and the extent of parasite replication in blood (percentage of infected erythrocytes measured at the indicated days postinfection),
appearance of neurological symptoms (CM phase, shaded area), and overall survival (percentage of surviving mice, total number of mice tested indicated)
were monitored. (A and B) Effect of prophylactic treatment regimen with CR-1-31B and (−)-SDS-1-021 on PbA infection parameters (survival and blood-stage
parasitemia). (C and D) Effect of different therapeutic treatment regimens (initiated at different days postinfection and given i.p.) with CR-1-31B on PbA
infection parameters. (E and F) Effect of different doses of CR-1-31B (0.02, 0.1, and 0.2 mg/kg) in a therapeutic regimen initiated at day 3 on PbA infection
parameters. Survival data were compared using the Mantel–Cox test, and significance was established relative to the vehicle (Veh)-treated mice; parasitemia
values were compared by ANOVA, followed by a Bonferroni posttest (indicated level of significance: *P < 0.05; **P < 0.01; ***P < 0.001). Ctrl, control.
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Effect of CR-1-31B on Host Inflammatory Response in Vivo. It is highly
desirable for new antimalarials to be effective once clinical
symptoms have started and, ideally, to be efficacious at a single
dosing. Therefore, we tested whether treatment with CR-1-31B
late during infection could blunt the development of disease and
cure infected animals. We observed that treatment of PbA-
infected mice with CR-1-31B starting at day 5 (when the first
neurological symptoms appear) and continuing until day 8 caused
significant protection against ECM in these mice (Fig. 5A). Fur-
thermore, we observed that even a single dosing of CR-1-31B at
either 0.2 or 0.5 mg/kg administered on day 5 had beneficial ef-
fects on disease and, at the higher dose, caused a significant in-
crease in overall survival of infected mice (Fig. 5B). This
intervention is similar to what is needed in human cases of CM,
where high mortality is associated with rapidly evolving and irre-
versible neurological symptoms. Finally, we note that the observed
therapeutic effect of a single dose of CR-1-31B given at day
5 occurs in the absence of a strong reduction in parasite load and
associated blood parasitemia measured at day 5 or 6 (Fig. 5C).
Excessive inflammatory response in situ is a major pathological
feature of ECM. This response is mediated, in part, by infiltration
of activated leukocytes in the brain, with concomitant production
of proinflammatory cytokines. Cells of the myeloid lineage play a
critical role in this pathological response, and mouse mutants
harboring reduced numbers or impaired activity of these cells
confer resistance in the ECMmodel (43, 44). The observation that
very late treatment with CR-1-31B can protect PbA-infected mice
against CM without affecting blood parasitemia (Fig. 5C) led us
to test the possibility that CR-1-31B may also have an impact on
the host inflammatory response in situ in the brain. Neuro-
inflammation in ECM is associated with breakdown of the blood–
brain barrier (BBB). An Evans Blue dye extravasation assay was
used to assess BBB integrity in PbA-infected mice (Fig. 5 D and
E). As opposed to the brains of PbA-infected B6 controls that
cannot exclude the blue dye, brains from CR-1-31B-treated mice
remained largely unstained, a feature that is indicative of an intact
BBB and is similar to what is observed in the ECM-resistant
mouse mutant, Irf8R294C (43) (Fig. 5 D and E). By flow cytom-
etry analysis, we observed reduced cellular infiltration of leuko-
cytes (Fig. S6A), of both CD11b+ myeloid cells (Fig. 6 A and B)
and TCRb+ lymphoid cells (Fig. 6 D and E and Fig. S6 B and C),
in the brain of CR-1-31B–treated mice compared with control
PbA-infected untreated mice. Reduced infiltration of inflamma-
tory cells in the brain coincided with reduced RNA expression of
genes encoding for the myeloid (Cebpd and C4b) and for the
lymphoid cell lineages (Gzmb, Cd3g, and Ifng) (Fig. 6 C and F and
Fig. S6D). Hence, ECM resistance in mice treated with CR-1-31B
correlates with reduced infiltration of leukocytes in the brain, re-
duced expression of proinflammatory genes in situ, and preser-
vation of BBB integrity.
Effect of CR-1-31B on Host Inflammatory Response in Vitro. Finally,
we directly tested the effect of different doses of CR-1-31B on
activation of isolated primary myeloid cells in response to IFN-γ,
which was monitored both by induction of the master proin-
flammatory transcription factor IRF1 and by production of early
inflammatory markers (GBP2 and CXCL10) (Fig. 7). The protein
level of STAT1, another proinflammatory transcription factor
downstream of IFN signaling that forms transcription complexes
with members of the IRF and ETS families to activate transcrip-
tion in response to proinflammatory stimuli (45), was not affected
by CR-1-31B exposure (Fig. 7A). On the other hand, exposure of
bone marrow-derived macrophages (BMDMs) to CR-1-31B sup-
pressed production of IRF1 (Fig. 7), a major transcriptional acti-
vator mediating myeloid cell activation in response to type I and
type II interferons, as well as other viral and bacterial stimuli. This
was associated with reduced expression of protein markers of ac-
tivation in these cells (GBP2) and production of the critical early
inflammatory chemokine CXCL10 (Fig. 7). The effect of CR-1-
31B on inflammatory protein production was dose-dependent and
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was not due to transcriptional inhibition. These results suggest that
rocaglates can also dampen host inflammatory function in myeloid
cells, with a beneficial impact on neuroinflammation that drives
pathogenesis in the ECM model.
Discussion
Rocaglates (flavaglines) are a class of natural products that we
have previously characterized as novel anticancer drugs (29).
These compounds act as potent inhibitors of translation initia-
tion by targeting eIF4A in two ways. They cause clamping of free
eIF4A onto RNA, resulting in complexes that may be sufficiently
stable to impair ribosome scanning if they occur in the mRNA 5′
leader regions and if they deplete eIF4A from the eIF4F com-
plex, resulting in decreased initiation events (31–34). Impor-
tantly, systemic suppression of eIF4F is well-tolerated at the
organismal level, increasing the therapeutic potential of roca-
glates (31, 46, 47). Recent studies have suggested that translation
is a potential target for antimalarial drug discovery (26). Indeed,
2,6-disubstituted quinoline-4-carboxamide analogs show strong
activity against different life forms of the human P. falciparum
parasite, targeting translation elongation factor 2 (PfEF2) (26).
Considering the high degree of structural and functional con-
servation among proteins involved in the translation machinery,
we investigated the possibility that rocaglates may (i) interact
with PfeIF4A and (ii) display antimalarial activity in in vivo and
ex vivo models of infection.
We obtained strong experimental evidence indicating that the
rocaglate CR-1-31B has direct antimalarial activity. First, we
demonstrate that CR-1-31B can stabilize complexes formed in
vitro between recombinant PfeIF4A and RNA, and this in a
manner similar to mammalian eIF4A1 tested under the same
conditions. Second, Plasmodium protein synthesis is inhibited by
low nanomolar concentrations of CR-1-31B in a 1-h radioactive
metabolic labeling assay and in a 24-h pLDH assay. Third, CR-1-
31B can block replication of P. falciparum in human erythrocytes
infected ex vivo, with IC50 values in the low nanomolar range.
Importantly, CR-1-31B shows similar IC50 values for P. falcipa-
rum clinical isolates from different regions of the world that
display diverse degrees of resistance to established antimalarial
drugs. Fourth, when tested in prophylactic and therapeutic
protocols, CR-1-31B protected mice against lethal CM caused by
infection with P. berghei. In all cases, the antimalarial effect of
CR-1-31B is dose- and exposure-dependent and is associated
with a significant decrease in blood parasitemia in treated mice.
Fifth, CR-1-31B is also active against P. chabaudi, a strict blood-
stage Plasmodium parasite that replicates rapidly in blood but
does not cause CM. Finally, it is important to note that a single
dose of CR-1-31B administered to P. berghei-infected mice at day
5, a time point at which control untreated infected mice display
early neurological symptoms (lethargy), is sufficient to signifi-
cantly improve survival and BBB integrity. Both single-dose cure
and novel modes of action with no cross-resistance to current
drugs are two key selection criteria in the global search for novel
antimalarial drugs (48, 49). Taken together, these studies es-
tablish that CR-1-31B has direct antiplasmodial activity by acting
on PfeIF4A, but we cannot formally exclude that CR-1-31B may
also affect other targets.
The rocaglate CR-1-31B was previously shown to have good
pharmacokinetic properties (35) that include high solubility and
membrane permeability at physiological pH. Incubation of CR-
1-31B in human plasma showed that it was 82–84% bound to
plasma proteins and that it was highly stable (100% remaining
after 3 h). Experiments with murine and human liver microsomes
demonstrated that CR-1-31B has a significant hepatic stability
(>95% after 1 h). In mice receiving repeated daily injections at
0.2 mg/kg, no observable toxic effects were detected and CR-1-
31B did not display toxicity toward cells of hematopoietic origin
(35). Altogether, these preliminary CR-1-31B pharmacological
and safety data suggest possible use in humans for CM.
Our studies extend those of Bhattacharya et al. (50) in doc-
umenting an antiinflammatory response by rocaglates. Impor-
tantly, we demonstrate that CR-1-31B, and related rocaglates, can
be used to interdict this process in the brain, highlighting its po-
tential use as an antimalarial drug for intervention in CM in hu-
mans. An antiinflammatory effect of CR-1-31B to dampen
neuroinflammation was initially suggested by results from single-
dosing experiments, where dramatic improvements in survival of
PbA-infected CR-1-31B–treated mice (i) occurred in the absence
of a substantial reduction in blood parasitemia (Fig. 5), (ii) were
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Fig. 4. Activity of CR-1-31B against different human P. falciparum isolates.
(A and B) Laboratory and field P. falciparum isolates were cultured in vitro in
human erythrocytes for 48 h in the presence of increasing doses
(0.1–100 nM) of CR-1-31B or CQ (1–500 nM). Cultures were stained with
SYBR-Green to quantify P. falciparum genomic DNA, and the results (rep-
resentative of two biological replicates) are shown as relative fluorescence
compared with the values measured at the lowest tested drug concentra-
tion. (C) Calculated IC50 values for CR-1-31B and CQ for all P. falciparum
isolates tested are shown as a histogram (average IC50 ± SD from two in-
dependent experiments).
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associated with decreased infiltration of myeloid and lymphoid
inflammatory cells in the brain and maintenance of the BBB in-
tegrity (Figs. 5 and 6), and (iii) led to reduced cerebral expression
of molecular markers of proinflammatory cells and inflammatory
mediators (i.e., Cebpd, Cd3g, Ifng, C4b, Gzmb) at the peak of
neuroinflammation (Fig. 6 and Fig. S6D). Finally, we showed that
exposure of myeloid cells to CR-1-31B causes a significant
dampening of the inflammatory response of these cells following
exposure to IFN-γ, as demonstrated by reduced protein expression
of the master transcriptional regulator IRF1 and the inflammatory
chemokine CXCL10 by these cells (Fig. 7). These findings
establish a rapid and beneficial antiinflammatory activity of
CR-1-31B during PbA-induced experimental CM and associated
neuroinflammation.
A possible explanation of these unexpected findings is that CR-
1-31B–mediated inhibition of mammalian eIF4A/eIF4F prefer-
entially inhibits translation of mRNAs encoding proinflammatory
effectors. There is a growing body of literature suggesting that
early activation of proinflammatory pathways involves regulation
at the level of translation, including proteins that are themselves
key transcriptional activators of the inflammatory response (51–
53). For example, Colina et al. (54) showed that translational
control is critical for expression of early defenses, including type I
IFN. They observed increased resistance to a number of viral in-
fections in 4E-BP1/2−/− mice, two redundant translational re-
pressors of eIF4F, and that this was associated with increased
production of type I IFN. They further demonstrated that 4E-BP1/
2 inactivation caused increased translation of the type I IFN
transcriptional activator IRF7 from existing RNA pools in plas-
macytoid dendritic cells. This establishes that the translational
repressors 4E-BP1/2 act as negative regulators of type I IFN and
that the translation of IRF7 is regulated by eIF4F (54). It is
tempting to speculate that inhibition of eIF4A by CR-1-31B could
likewise dampen early proinflammatory responses such as type I IFN,
thereby benefiting the host under situations that arise such as CM,
where pathogenesis is driven by acute inflammation. Indeed, we and
others have previously reported rapid activation of the IFN response
in situ in the brain of PbA-infected mice, and have shown that in-
activation of Irf7 and other genes that are part of this response (IFN-
stimulated genes:Usp15, Trim25, Stat1, Irf1, Irf3, Irf8, and Socs1/Socs3)
causes resistance to CM (43, 55, 56). These findings are consistent
with the proposal that inhibition of translation initiation in general,
and of eIF4A in particular, dampens the inflammatory response.
Our studies also tease out an important functional property of
rocaglates in Plasmodium-infected mice: the ability to act as dual-
targeting agents displaying strong antimicrobial activity against this
parasite while also dampening the acute inflammatory response in
infected brains of the host. The end result is a potent perturbation
of parasite replication and pathogenesis at low nanomolar con-
centrations. These properties, documented in preclinical models
of blood-stage and cerebral disease, make CR-1-31B a high-profile
candidate for intervention in CM in humans. The efficacy of CR-
1-31B and other rocaglates against human malaria will require
future testing in clinical studies either alone or in combination
with Art, which is the current standard of care for CM.
Materials and Methods
Mice and Murine Plasmodium Parasites. Eight-week-old female C57BL/6 mice
were purchased from the Charles River Laboratories. Mouse mutant strains
carrying loss of function at either Irf8 (Irf8R294C; Irf8m/m) (43) or Themis
(ThemisI23N) (40) are on a C57BL/6 background and are resistant to CM as
previously described. All mice were housed at McGill University Animal Care
Center according to the guidelines of the Canadian Council on Animal Care.
All protocols were approved by the Animal Care Committee of McGill Uni-
versity (Protocol 5287), and include procedures to minimize distress and
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Fig. 5. CR-1-31B–mediated protection against neuroinflammation in late-stage CM. (A) Effect of a therapeutic regimen with CR-1-31B (0.2 mg/kg; four daily
i.p. injections) initiated at day 5 post-PbA infection on survival (significance determined using the Mantel–Cox log-rank test: ***P < 0.001). Veh, vehicle.
(B and C) Effect of late-stage, single high doses of CR-1-31B (0.2 mg/kg and 0.5 mg/kg) given i.p. at day 5 on infection parameters in PbA-infected mice. The
effects on survival (B) and on blood-stage parasitemia (C) are shown. Parasitemia levels were compared using ANOVA with a Bonferroni posttest. (D) Integrity
of the BBB in normal mice (NI) and PbA-infected mice treated with Veh or CR-1-31B (single 0.5-mg/kg dose, i.p., day 5) was assessed by Evan’s Blue ex-
travasation assay. The CM-resistant Irf8R294C mutant mice (43) were included as positive controls. (E) Evan’s Blue dye accumulation in the brain was quantified
and expressed as micrograms per gram of brain tissue. Data are presented as mean ± SD, and groups were compared using an unpaired Student’s t test (*P <
0.05; **P < 0.01; ***P < 0.001).
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improve welfare. An isolate of PcA was provided by Mary M. Stevenson,
McGill University Health Center Research Institute, and was maintained by
weekly passage in A/J mice for a maximum of four consecutive passages, as
previously described (41). An isolate of PbA was initially obtained from the
Malaria Reference and Research Reagent Resource Center (MR4); PbA was
passaged in C57BL/6J (B6) mice for a maximum of three consecutive passages
(57). In passage mice, blood parasitemia was monitored by calculating the
percentage of pRBCs on thin blood smears stained with Diff-Quick (Dade
Behring), as described (41). Infected blood was diluted in pyrogen-free saline
for infection of experimental animals.
Human Plasmodium Parasites. Several different P. falciparum isolates were
used to test the antimalarial activity of CR-1-31B. These included four freshly
isolated clones from patients seen at The University of Toronto Health Network
of the University of Toronto (UHN1–4). We also tested standard laboratory lines
3D7, ItG, CS2, and FCR3, as well as recent isolates from Thailand showing a low
level of CQ and mefloquine resistance (MS-97 isolates).
All P. falciparum clones were mycoplasma-free and were maintained in
continuous culture with fresh O+ erythrocytes from healthy blood donors as
previously described (58). Ring-form cultures were synchronized with 5%
sorbitol treatment twice over two intraerythrocytic cycles (59). To assess the
antimalarial activity of the drugs tested, we used a SYBR-Green method to
quantify parasite genomic DNA (60). Briefly, a 96-well plate with a series of
twofold dilutions was produced containing R-10G medium plus drug and R-
10G medium alone (last well). The parasite culture, 1% hematocrit and 2%
parasitemia, was added to each well, and the plates were incubated at 37 °C
and gassed (93% N2, 5% CO2, and 2% O2) for 48 h. Relative fluorescence was
assessed using a Biotek Synergy-4 Multi-Mode Microplate Reader (Biotek
Instruments, Inc.) and a Fluostar Optima plate reader (BMG Labtech). The
IC50 values of CR-31 or CQ for individual isolates were determined using a
four-variable nonlinear regression analysis of the relative fluorescence of
individual wells following the addition of SYBR-Green I using GraphPad
Prism v7.0 software.
In vitro P. falciparum protein inhibition was performed by using a Plas-
modium-specific LDH assay (61) after a 24-h incubation period and de-
termining the absorbance at 595 nm using a plate reader. Briefly, compounds
were dissolved in DMSO solution before being used to prepare serial twofold
dilutions across a 96-well plate. Parasite culture material was then added to
give a final hematocrit of 2% and a parasitemia of 2%, and the plate was then
incubated for 24 h at 37 °C in an atmosphere of 95% N2, 3% CO2, and 2% O2.
The IC50 values of CR-1-31B and CHX were determined using a four-variable
nonlinear regression analysis using GraphPad Prism v7.0 and represent the
mean ± SEM (n = 4).
Protein Sequence Alignment. Human (NP_001407.1) and murine (NP_659207.1)
eIF4A1 protein sequences were retrieved from the National Center for Bio-
technology Information Refseq database. The murine eIF4A1 protein sequence
was used as input in the PlasmoDB BLASTp tool to identify similar proteins in
Plasmodium parasites. Putative PfeIF4A proteins were identified in all human
and murine parasites, having 70% sequence identity and 83–84% sequence
similarity. Plasmodium protein sequences were downloaded from PlasmoDB (62)
for P. falciparum 3D7 (PF3D7_1468700), Plasmodium vivax Sal-1 (PVX_117030),
Plasmodium knowlesi strain H (PKNH_1212500), PbA (PBANKA_1331900), and
P. chabaudi AS (PCHAS_1336500). Multiple sequence alignment was performed
using Clustal Omega (63) and was visualized with Jalview v.2 (64) (Fig. S1).
Infections. Mice were infected i.v. (0.2 mL) with 107 P. chabaudi pRBCs or 106
PbA into the tail vein and monitored under biosafety level 2 containment
conditions. At predetermined times postinfection, blood was sampled, and
blood parasitemia was determined (five fields of >100 erythrocytes were
counted per mouse, and results are expressed as the percentage of para-
sitized erythrocytes) following staining of thin blood smears with Diff-Quick.
P. berghei-infected mice were similarly monitored for blood parasitemia, but
also for the appearance of neurological symptoms (shivering, tremors, ruf-
fled fur, seizures, and paralysis), and were euthanized when reaching clinical
or experimental end points. Survival curves were compared using the
Mantel–Cox log-rank test.
Plasmodium Metabolic Labeling. Irf8m/m mice were infected i.p. with PbA
pRBCs and monitored for parasitemia. When the blood parasitemia reached
10–15%, blood and was recovered by cardiac puncture in heparinized tubes.
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Fig. 6. CR-1-31B–mediated protection against neuroinflammation is associated with reduced infiltration of immune cells. PbA-infected mice were perfused,
and the effect of CR-1-31B on the total number of infiltrating cells, both CD11b+ myeloid cells (A) and TCRb+ lymphoid cells (D), was determined by FACS
analysis. Scatter plots for primary FACS data are shown for CD11b+ myeloid cells (B) and lymphoid cells (E) obtained from noninfected (NI) and PbA-infected
mice treated i.p. with vehicle (Veh) or CR-1-31B. P values were calculated by ANOVA, followed by a Bonferroni posttest. (C and F) Relative mRNA expression
(expr.) for representative myeloid (Cebpd) and lymphoid (Gzmb) cell markers in the brain of CR-1-31B–treated and control PbA-infected mice, as determined
by RT-qPCR. Data were normalized to Hprt, used as an internal control, and are expressed relative to noninfected controls (P values were calculated using an
unpaired Student’s t test: *P < 0.05; ***P < 0.001).
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Blood was washed three times with 1 vol of cold methionine-free RPMI 1640
(ThermoFisher) and resuspended to 5% hematocrit in RPMI 1640 methionine-
free medium containing L-glutamine (2 mM), 10% heat-inactivated charcoal-
filtered FBS, 0.15 mM hypoxanthine, and 25 mM Hepes. Ninety-six–well plates
containing 5 μL of vehicle or an increasing concentration (from 1 nM to 10 μM)
of CHX, CR-1-31B, or CQ were supplemented with 90 μL of PbA-infected blood
(or noninfected blood) and incubated at 37 °C for 30 min. Cells were then
labeled by addition of [35S]-Met (150–225 μCi/mL; PerkinElmer), followed by
incubation for 30 min at 37 °C. At the end of the labeling procedure, plates
were immediately put on ice and cold PBS was added. Plates were centrifuged
for 10 min at 500 × g at 4 °C, supernatant was removed, and erythrocyte
pellets were lysed by addition of 40 μL of lysis buffer (1× PBS, 0.15% saponin,
and 0.02% sodium deoxycholate), followed by incubation for 15 min 4 °C with
agitation. Twenty microliters of lysate was used for TCA precipitation, and
radioactivity was determined by scintillation counting. Also, 5 μL of one rep-
licate was analyzed on 10% SDS/PAGE; the gels were treated with En3Hance
(PerkinElmer), dried, and exposed to Kodak BioMax XAR Film for 36 h at 20 °C.
Drugs and Drug Treatments. CQ hydrochloride (Sigma) was prepared in PBS,
while Art (artesunate; a gift from Dafra Pharmaceuticals, Turnout, Belgium)
was prepared fresh in 5% sodium bicarbonate. Asymmetrical synthesis of CR-
1-31B and (−)-SDS-1-021 using biomimetic kinetic resolution of chiral, race-
mic aglain ketone precursors was performed as previously published (38, 65)
followed by amide formation (39). Purity of the rocaglate derivatives
CMLD010513 [(−)-CR-1-31B] and CMLD011604 [(−)-SDS-1-021] was assessed
using UPLC-MS-UV-ELSD analysis (Fig. S2). A Waters Acquity UPLC instrument
(with a binary solvent manager, single quadrupole (SQ) mass spectrometer,
and Waters 2996 photodiode array detector) and an ELSD instrument were
used with an Acquity UPLC BEH C18 1.7-μm column. For the analysis, a sol-
vent gradient of 10–90% acetonitrile in water over 2 min, followed by 1 min
of 90% acetonitrile, was employed.
For drug treatments, CR-1-31B and (−)-SDS-1-021 were solubilized in 100%
DMSO and freshly diluted in sterile PBS to the required concentration with
10% DMSO. Vehicle-treated mice received PBS containing 10% DMSO only.
The antimalarial activity of CR-1-31B and (−)-SDS-1-021 was tested according
to experimental protocols we have previously described (57).
Evans Blue Dye Extravasation. At day 6 postinfection with PbA, 24 h after
receiving a single dose (0.5 mg/kg) of CR-1-31B, groups of mice were injected
i.v. with 0.2 mL of 1% Evans Blue dye (E2129; Sigma) prepared in sterile PBS.
The dye was allowed to circulate for 1 h, and mice were then exsanguinated
by cardiac puncture and perfused with PBS containing 2 mM EDTA. Brains
were excised, weighed, imaged, and incubated with 1 mL of dimethyl
formamide for 48 h to extract Evan’s Blue dye from the tissues. The optical
density of 50 μL of dimethyl formamide that received brain Evan’s Blue dye
was measured at 620 nm, and measurements were converted into micro-
grams of dye extravasated per gram of tissue by interpolation of a standard
curve from serial dilutions of Evan’s Blue dye in dimethyl formamide.
Leukocyte Infiltration in the Brain. Six days postinfection with PbA, groups of
mice that received single-dose treatment on day 5 were exsanguinated and
perfused as above. Brains were harvested; Dounce-dissociated; and ho-
mogenized in RPMI media containing 0.5 mg/mL collagenase D (Gibco Life
Technologies), 0.01 mg/mL DNase I (Roche), and 2 mM EDTA. Infiltrating cells
were separated on a 34% Percoll solution. Cells were counted and stained for
flow cytometry analyses with the following: Zombie AquaDye-V500 (BioLegend),
anti–CD4-peridinin chlorophyll protein complex (PerCP)-Cyanine5.5 (clone RM4-
5; eBioscience), anti–CD8α-eFluor450 (clone 53-6.7; eBioscience), anti–TCR-
β–phycoerythrin (PE) (clone H57-597; eBioscience), anti–B220-FITC (RA3-6B2;
eBioscience), CD69-BV605 (H1.2F3; BD Bioscience), CD44-PE-Cy7 (clone IM7;
eBioscience), anti–CD11b-eFluor450 (clone M1/70; eBioscience), anti–CD11c-
PerCP-Cyanine5.5 (clone N418; eBioscience), and anti–Ly6G-FITC (clone 1A8;
BioLegend). Flow cytometry was performed on a BD LSRFortessa (BD Bioscience)
and analyzed using FlowJo software v.10. A fraction of total brain cells, before
Percoll separation, were lysed, and total RNA was prepared using RNeasy
columns (Qiagen). cDNA was synthesized with Moloney murine leukemia
virus reverse transcriptase (Thermo Fisher Scientific). Myeloid and lymphoid
markers, as well as IFN-stimulated gene expression levels, were assessed by
qPCR using SsoAdvanced SYBR-Green Supermix (BioRad), and gene ex-
pression was normalized to Hprt; oligonucleotide sequences were described
previously (55). Fold changes in gene expression were expressed relative to
noninfected mice.
Preparation of BMDMs. BMDMs were differentiated from bone marrow iso-
lated from the femur and tibia of 8- to 16-wk-old C57BL/6 mice, as described
previously (45). Briefly, bone marrow cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Wisent) containing 10% heat-inactivated
FBS, antibiotics, and 20% L cell-conditioned medium (LCCM). The cells were
supplemented with 10% LCCM 4 d later, and at day 6, cells were harvested
by gentle washing of the monolayer with PBS-citrate. Cells were plated in
tissue culture-grade six-well dishes in DMEM containing 10% FBS and 20%
LCCM, and were used the next day.
Molecular Biology. A codon-optimized variant of PfeIF4A (XM_001348793.1)
for increased bacterial expression was synthesized by Genscript and cloned
into pET15b utilizing NdeI and BamHI restriction sites. The resulting plasmid
was transfected in BL21(DE3) codon+ E. coli cells, and the overexpressed
protein was purified using nickel affinity (HiTrap IMAC FF; GE Healthcare),
anion exchange (HiTrap Q HP; GE Healthcare), and gel filtration (Superdex
200 10/300 GL; GE Healthcare) chromatography. Fractions containing
PfeIF4A were pooled and concentrated using Amicon Ultra centrifugal filter
units. The construct pET15b/eIF4AI for expression of murine eIF4AI has been
described previously (66).
The ability of different compounds to affect binding and retention of
eIF4A to RNA templates was determined using purified recombinant proteins
and [32P]-labeled RNA templates as previously described (31). To monitor the
effect of CR-1-31B on the proinflammatory response of primary macro-
phages, whole-cell protein extracts were prepared and analyzed by SDS/
PAGE. Immunoblotting was performed using primary antibodies directed
against IRF1 (sc-640), STAT1 (sc-591), and GBP2 (sc-10588) (all from Santa
Cruz Biotechnology); CXCL10 (R&D Systems); and B-Actin (EMD Millipore),
and it was revealed using IR680 or IR800-conjugated secondary antibodies
(Li-Cor). Protein band intensities were measured using Image Studio Lite
software (Li-Cor) and normalized against B-Actin protein level.
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Fig. 7. CR-1-31B blocks IFN-γ (IFNg)–induced production of inflammatory
proteins in myeloid cells. (A) Whole-cell extracts from wild-type BMDMs
treated or not treated with IFN-γ in combination with increasing doses of CR-
1-31 for 3 or 6 h, were used to monitor expression of a series of diagnostic
proinflammatory proteins (IRF1, CXCL10, STAT1, and GBP2) by immuno-
blotting, using actin as an internal control. (B) Quantification of IRF1 and
CXCL10 protein expression from A [relative arbitrary units (AU), normalized
to actin].
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